Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Up Following Analyst Upgrade

Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) gapped up prior to trading on Monday after JPMorgan Chase & Co. raised their price target on the stock from $32.00 to $36.00. The stock had previously closed at $14.96, but opened at $15.39. JPMorgan Chase & Co. currently has an overweight rating on the stock. Day One Biopharmaceuticals shares last traded at $14.91, with a volume of 150,318 shares traded.

Several other research firms have also recently weighed in on DAWN. Oppenheimer reissued a "market perform" rating on shares of Day One Biopharmaceuticals in a research report on Tuesday, February 27th. The Goldman Sachs Group cut their price objective on Day One Biopharmaceuticals from $50.00 to $44.00 and set a "buy" rating on the stock in a research report on Tuesday, February 27th. Finally, Piper Sandler restated an "overweight" rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a research note on Tuesday, March 26th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, Day One Biopharmaceuticals has an average rating of "Moderate Buy" and an average target price of $39.83.

Insider Buying and Selling at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, General Counsel Adam Dubow sold 3,242 shares of the business's stock in a transaction on Friday, February 16th. The stock was sold at an average price of $15.25, for a total value of $49,440.50. Following the sale, the general counsel now directly owns 16,585 shares in the company, valued at $252,921.25. The sale was disclosed in a filing with the SEC, which is accessible through this link. In related news, General Counsel Adam Dubow sold 3,242 shares of the business's stock in a transaction on Friday, February 16th. The stock was sold at an average price of $15.25, for a total transaction of $49,440.50. Following the sale, the general counsel now directly owns 16,585 shares in the company, valued at approximately $252,921.25. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Charles N. York II sold 2,666 shares of the business's stock in a transaction on Friday, February 16th. The shares were sold at an average price of $15.25, for a total value of $40,656.50. Following the sale, the chief financial officer now owns 277,754 shares in the company, valued at $4,235,748.50. The disclosure for this sale can be found here. Insiders have sold a total of 45,781 shares of company stock worth $722,960 over the last ninety days. 8.40% of the stock is currently owned by company insiders.

Institutional Trading of Day One Biopharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. increased its stake in Day One Biopharmaceuticals by 130.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,226 shares of the company's stock worth $27,000 after acquiring an additional 1,262 shares during the last quarter. Quest Partners LLC bought a new position in Day One Biopharmaceuticals in the 4th quarter worth about $29,000. Quintet Private Bank Europe S.A. increased its stake in Day One Biopharmaceuticals by 43.2% in the 4th quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company's stock worth $48,000 after acquiring an additional 1,000 shares during the last quarter. Amalgamated Bank increased its stake in Day One Biopharmaceuticals by 35.7% in the 3rd quarter. Amalgamated Bank now owns 8,628 shares of the company's stock worth $106,000 after acquiring an additional 2,268 shares during the last quarter. Finally, Exchange Traded Concepts LLC increased its stake in Day One Biopharmaceuticals by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 10,072 shares of the company's stock worth $147,000 after acquiring an additional 2,554 shares during the last quarter. 87.95% of the stock is currently owned by institutional investors.

Day One Biopharmaceuticals Stock Performance

The firm has a market capitalization of $1.34 billion, a P/E ratio of -6.46 and a beta of -1.48. The business has a 50 day simple moving average of $15.22 and a two-hundred day simple moving average of $13.75.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last posted its quarterly earnings data on Monday, February 26th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.57) by ($0.07). On average, equities analysts anticipate that Day One Biopharmaceuticals, Inc. will post -2.66 earnings per share for the current fiscal year.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.